CADL - Company ID 0001841387
The table below shows Candel Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $9.84M | $8.46M | $6.99M | $4.02M | $5.42M | $4.98M |
| SG&A |
Candel Therapeutics, Inc. reported annual revenue of $125.00K for fiscal year 2022. That is up 0.0% from $125.00K in fiscal 2021. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $6.44M |
| $4.75M |
| $4.19M |
| $4.11M |
| $3.34M |
| $3.59M |
| Operating income | -$16.28M | -$13.21M | -$11.18M | -$8.13M | -$8.76M | -$8.57M |
| Income tax | - | - | - | - | - | - |
| Net income | -$8.86M | -$11.27M | -$4.80M | $7.38M | -$10.65M | -$22.24M |
| EPS (diluted) | -$0.14 | -$0.21 | -$0.09 | $0.13 | -$0.33 | -$0.74 |